Pipeline breakthroughs & novel mechanisms
Key Questions
What anti-amyloid therapies are expanding globally?
Lecanemab and donanemab continue global expansion, while Auvelity received FDA approval for agitation in Alzheimer's. Real-world data on Zunveyl in long-term care shows improvements in cognition, behavior, and GI tolerability.
What is karyoptosis and its relevance to Alzheimer's?
Karyoptosis is a newly discovered cell death mechanism involving p38 MAP kinase and LaminB1 that affects over a third of cells in Alzheimer's and FTD, opening new therapeutic targets beyond traditional amyloid and tau pathways.
How might gene therapy or TREM2 mechanisms help Alzheimer's?
Novel mechanisms under study include gene therapy, TREM2 modulation, tau-focused approaches, and a copper-based drug that restored memory in mice. Arc protein is being explored as a Trojan horse for tau spread.
What non-invasive brain stimulation shows strongest evidence?
An umbrella review of 42 meta-analyses confirmed rTMS as the most effective non-invasive brain stimulation for cognitive benefits in Alzheimer's, with additional promise from tanycytes as a CSF-to-blood bridge for tau clearance.
Did semaglutide succeed in Alzheimer's trials?
Phase 3 trials of semaglutide failed to slow clinical decline despite biomarker improvements, highlighting the gap between biomarker changes and meaningful cognitive outcomes.
What role does exercise play in new Alzheimer's interventions?
Exercise snacking studies propose repeated exerkine spikes like BDNF as a novel non-pharmacological approach, while prodrug strategies converting hydrogen peroxide into drug activators showed cognitive gains in animal models.
How are resilient brains different in Alzheimer's research?
Resilient brains exhibit lower inflammation signals in immature neurons rather than more neurons overall, challenging neuron replacement strategies and pointing to inflammation modulation via cPLA2 enzymes in APOE4 carriers.
What new therapeutic targets are emerging from recent discoveries?
Targets include peripheral immune proteins identified via PWAS, astrocytic calcium signaling in default mode network dysfunction, and rapamycin analogs, with a $3M USC gift funding APOE4-driven neuroinflammation research.
Anti-amyloid therapies (lecanemab, donanemab) expanding globally; Auvelity FDA-approved for agitation. Novel mechanisms: gene therapy, TREM2, tau-focused, copper-based drug (memory restoration in mice), rapamycin analog. Major discovery: 'karyoptosis'—novel cell death mechanism (p38 MAP kinase/LaminB1) in Alzheimer's and FTD, over a third of cells affected, opening new therapeutic targets. Arc protein as Trojan horse for Tau spread. PWAS identifies peripheral immune proteins as potential targets. Astrocytic calcium signaling as early driver of default mode network dysfunction. New discovery: resilient brains show lower inflammation signals in immature neurons, not more neurons—challenges neuron replacement ideas. Setback: Phase 3 trial of semaglutide in Alzheimer's failed to slow clinical decline despite biomarker improvement. $3M gift to USC targets APOE4-driven neuroinflammation via cPLA2 enzymes. New: umbrella review of 42 meta-analyses confirms rTMS as most effective non-invasive brain stimulation for cognitive benefits. New: 'Exercise Snacking' study proposes repeated exerkine spikes (BDNF) as novel non-pharmacological intervention. New: prodrug strategy turning hydrogen peroxide into drug activator shows cognitive improvement in animal models. New: tanycytes identified as direct CSF-to-blood bridge for Tau clearance. Comprehensive minireview consolidates AD pathophysiology, current treatments, and future directions including herbal adjuncts. New: real-world data on Zunveyl in long-term care shows provider-reported improvements in cognition, behavior, and GI tolerability, with potential to reduce psychotropic use. New: neuroinflammation review consolidates mechanistic links, targets, and therapies—reinforces inflammation as therapeutic axis. AAIC conference may bring next-gen drug updates.